Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

68 69 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 28, 2024

Via Benzinga

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why ↗

March 28, 2024

The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.

Via Investor's Business Daily

3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗

March 26, 2024

These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.

Via InvestorPlace

If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today ↗

March 25, 2024

Via Benzinga

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗

March 25, 2024

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Via InvestorPlace

$100 Invested In This Stock 15 Years Ago Would Be Worth $1,500 Today ↗

February 27, 2024

Via Benzinga

FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease”

March 25, 2024

Via AB Newswire

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

March 21, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 Biopharma Stocks Predicted to Soar in Q2 2024 ↗

March 20, 2024

These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals.

Via InvestorPlace

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

March 20, 2024

Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel

Via MarketBeat

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires ↗

March 19, 2024

These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.

Via InvestorPlace

2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗

March 17, 2024

It's always a good time to buy great stocks with excellent prospects.

Via The Motley Fool

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation ↗

March 17, 2024

There's no need for delays in buying these great stocks.

Via The Motley Fool

Forget Tesla, Buy This Magnificent Healthcare Stock Instead ↗

March 17, 2024

Vertex Pharmaceuticals already has a fantastic business, and it could get much bigger in the future.

Via The Motley Fool

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗

March 09, 2024

Good news could be in store for all three of these drugmakers.

Via The Motley Fool

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years ↗

March 08, 2024

Via Benzinga

The Top 3 Biotech Stocks to Buy in March 2024 ↗

March 06, 2024

Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors.

Via InvestorPlace

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market ↗

March 05, 2024

All three have exciting programs on the way.

Via The Motley Fool

Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making ↗

March 05, 2024

These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward.

Via InvestorPlace

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗

March 04, 2024

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Via InvestorPlace

ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential ↗

March 04, 2024

Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential.

Via InvestorPlace

Topics Artificial Intelligence

Why Editas Medicine Stock Soared as Much as 42% Higher This Week ↗

March 02, 2024

The clinical-stage genome editing company dropped a couple of important announcements for shareholders.

Via The Motley Fool

3 Magnificent Growth Stocks to Buy in March ↗

March 02, 2024

These three stocks have two important common denominators: the same industry and tremendous growth prospects.

Via The Motley Fool

Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List ↗

March 01, 2024

Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant.

Via Benzinga

These 4 Stocks Are the "Magnificent Seven" of Healthcare ↗

March 01, 2024

Their growth trajectories aren't as meteoric, but they're still notable.

Via The Motley Fool

Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks? ↗

February 29, 2024

These stocks meet many of the criteria long-term investors look for.

Via The Motley Fool

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗

February 27, 2024

Both companies are working on treatments for genetic disorders.

Via Investor's Business Daily

3 Biotech Stocks Bound to Blast Off By 2029 ↗

February 27, 2024

Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years.

Via InvestorPlace

bluebird bio: How to play LEAPS options for growth and income

February 27, 2024

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT

Via MarketBeat

Vertex Pharmaceuticals (VRTX) Should Remain Supported ↗

February 27, 2024

Vertex Pharmaceuticals Incorporated (VRTX), is a biotechnology company. It engages in developing & commercializing therapies for treating cystic fibrosis (CF).

Via Talk Markets

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vertex Pharmaceuticals (NQ:VRTX)

All News about Vertex Pharmaceuticals

Starting at $3.75/week.

Subscribe Today